Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 12 Brain Neoplasms 6 Gliosarcoma 5 Astrocytoma 4 Recurrence 3 Oligodendroglioma 3 Lymphoma, Follicular 3 Carcinoma, Non-Small-Cell Lung 3 Prostatic Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Optic Nerve Glioma 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Immunoblastic Lymphadenopathy 2 Hodgkin Disease 2 Glioma 2 Diffuse Intrinsic Pontine Glioma 2 Central Nervous System Neoplasms 2 Burkitt Lymphoma 2 Waldenstrom Macroglobulinemia 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1

Interventions

pembrolizumab 157 Gemcitabine 140 Capecitabine 123 Paclitaxel 121 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Docetaxel 98 Leucovorin 97 Cisplatin 90 Radiosurgery 88 Irinotecan 88 Carboplatin 86 Cyclophosphamide 72 Cetuximab 72 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Cilengitide × Clear all

NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡